Alembic Pharmaceuticals Limited — PPTs, 05-08-2025: Investor Presentation

**1. Financial Highlights:**

Alembic Pharma's unaudited Q1 FY26 delivered strong results: Revenue INR 1,711 Cr (+10% YoY), EBIDTA INR 288 Cr (+20% YoY, 17% margin), and Net Profit INR 155 Cr (+26% YoY, 9% margin). US Generics and Ex-US Generics led segment performance, with India Branded Business also growing. API was broadly flat.

**2. Strategic Initiatives & Growth Drivers:**

Future growth is driven by 15+ US Generics launches expected in FY26 from new facilities and continued Ex-US Generics expansion. Strategic tech adoptions like new sales tools and AI are boosting operational efficiency and market reach.

**3. Business Developments:**

Q1 FY26 included 4 new US product launches and 6 final ANDA approvals. Recent highlights: 2025 commissioning of Indore facility and acquisition of Utility Therapeutics Limited. The Animal Health division also saw robust growth.

**4. Market Position & Competitive Advantage:**

Alembic ranks among top Indian pharma players and leads in certain Animal Health segments. Its competitive edge stems from an established US generics footprint, extensive global API supply, and a developing specialty drug pipeline for India.

**5. Investor Implications:**

Strong Q1 FY26 results, particularly in Generics, signal positive growth potential. Strategic investments in pipeline and technology position for future expansion. Investors should monitor the API segment's ability to manage pricing pressures.